Jeffrey Trigilio - Sep 8, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Financial Officer
Signature
/s/ Jeffrey Trigilio
Stock symbol
CGEM
Transactions as of
Sep 8, 2021
Transactions value $
-$362,653
Form type
4
Date filed
9/9/2021, 04:15 PM
Next filing
Oct 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $64.5K +15K +666.67% $4.30 17.3K Sep 8, 2021 Direct
transaction CGEM Common Stock Sale -$153K -5.49K -31.81% $27.83 11.8K Sep 8, 2021 Direct F1, F2
transaction CGEM Common Stock Sale -$274K -9.51K -80.87% $28.85 2.25K Sep 8, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -15K -5.93% $0.00 238K Sep 8, 2021 Common Stock 15K $4.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.40 to $29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.